Biopharma AI
ByIs AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26 the Turning Point Where AI Becomes Industrial-Scale Drug Discovery?
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened with a defining…
Lantern Pharma Secures FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas, Expanding AI-Driven Precision Oncology Strategy
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food…
Can Insilico Medicine’s Hong Kong IPO Signal a Turning Point for AI-Driven Drug Discovery in Global Capital Markets?
Hong Kong | January 4, 2026 Insilico Medicine, a China-based, AI-driven drug discovery company backed by Qiming Venture…
Can Eli Lilly’s Orforglipron Overtake Novo Nordisk’s Rybelsus in the Race for Oral GLP-1 Leadership?
Indianapolis, Ind., 2026 — Eli Lilly and Company today announced positive head-to-head Phase 3 results demonstrating that its…
Is Johnson & Johnson Preparing to Divest DePuy Synthes in a $20 Billion Strategic Pivot Toward Pharmaceuticals?
Will Johnson & Johnson’s Orthopedics Review Reshape the Global MedTech Landscape? Johnson & Johnson is reportedly exploring a…
